Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pearl Therapeutics names new CEO
As Pearl Therapeutics’s new CEO, Mr Karsen brings more than 25 years of experience in the biotechnology and pharmaceutical industries. Most recently, Mr Karsen served as regional president
As Pearl Therapeutics’s new CEO, Mr Karsen brings more than 25 years of experience in the biotechnology and pharmaceutical industries. Most recently, Mr Karsen served as regional president
The financing will allow FlexGen to speed up the development and global commercialization of its FlexArrayer, an instrument that provides researchers with unprecedented freedom in the production of
Prior to joining LabCorp, Dr Brecher served as vice chair of the department of pathology and laboratory medicine at the McLendon Clinical Laboratories, University of North Carolina Hospitals.
The study will evaluate MORAb-009, plus the chemotherapy drugs pemetrexed and cisplatinum, as a first-line treatment for patients with mesothelioma. The primary objective of the study is to
According to the company, Mr Lusk will lead the national sales force, manage international distribution, and drive activities to market the Celerus Wave System, the first and only
Acording to Nitinol Devices & Components (NDC), this anchoring technology integrates the superelastic material properties of nitinol with proprietary anchoring design elements to provide secure fixation and removability
The agreement initially entails evaluation of one of the company’s nanoviricide drug candidates by an independent consultant chosen by the party. This drug candidate has been designed to
Mr Mahaffy brings significant biotechnology and pharmaceutical executive management experience. Mr Mahaffy was the founder of Pharmion and served as its president and CEO from its inception through
According to the company, the Avidoxy defense kit (DK) includes Avidoxy (doxycycline tablets), a broad spectrum oral antibiotic, in an easy-to-swallow film-coated caplet indicated as adjunctive therapy for
Pfizer will apply Xencor’s Xtend antibody half-life prolongation technology and XmAb antibody-dependent cell-mediated cytotoxicity enhancing technology to its antibody drug candidates. Under the terms of the agreement, Pfizer